≥99% HPLCPre-filled pen

Ipamorelin

Name: Ipamorelin
Brand: Dripfy
Availability: InStock

What it is?

Ipamorelin is a selective growth hormone secretagogue studied for its ability to stimulate endogenous growth hormone (GH) release via ghrelin-receptor pathways. It is commonly positioned for protocols targeting recovery, body composition, and sleep-related regeneration, with an emphasis on a cleaner signalling profile versus broader secretagogues.

Dripfy Advantage

Receptor engagement: Acts primarily through growth hormone secretagogue receptor (GHSR-1a) signalling to promote GH release.
Selectivity profile: Positioned as a more selective secretagogue, with research use often highlighting limited activation of prolactin- and cortisol-associated pathways.
Pulsatile GH dynamics: Supports pulsatile GH release patterns, aligning more closely with physiological secretion rhythms rather than continuous stimulation.
Downstream cascade alignment: By increasing endogenous GH signalling, it is associated with downstream effects on IGF-1 axis activity and recovery-related anabolic pathways.
Recovery–sleep interface: Frequently positioned in protocols where sleep architecture and recovery kinetics are relevant endpoints.

Clinical Applications & Therapeutic Potential

Endogenous GH axis support: Increased GH pulse signalling with downstream endocrine pathway activation relevant to adaptation models.
Body composition endpoints: Support for fat-loss signalling while preserving lean-mass markers in structured diet and training contexts.
Recovery kinetics: Improved recovery-related signalling following training stress, including reduced perceived fatigue markers in observational protocols.
Sleep quality indices: Association with improved sleep-depth markers and next-day recovery readiness endpoints (protocol-dependent).

Composition & Formulation

Peptide content: 5 mg CJC-1295 No DAC + 10 mg Ipamorelin
Vehicle: Proprietary pH-balanced buffer solution
Delivery system: Pre-filled, multi-dose, closed-system pen
Total volume: 3 mL
Purity: ≥99% for both peptides by HPLC/MS

€374

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Ipamorelin

Selective growth hormone secretagogue / ghrelin-receptor (GHSR-1a) agonist (investigational) · Pre-filled pen

C· Emerging evidence

Ipamorelin is studied as a selective growth-hormone secretagogue that acts on the ghrelin / growth-hormone-secretagogue receptor (GHSR-1a) to prompt the pituitary to release the body's own growth hormone in a pulsatile pattern. Research emphasises a comparatively selective profile, with limited activation of prolactin- and cortisol-linked pathways relative to broader secretagogues. Long-term human outcome data remain limited.

Studied use areas

Research into stimulation of the body's own GH release
Recovery and tissue-regeneration research
Body-composition and lean-mass research
Sleep-related recovery research

Safety & status

Educational information only — not medical advice; use requires physician supervision
Investigational and not an approved therapy for these uses
Stimulating the GH axis can affect glucose metabolism and fluid balance, so suitability and monitoring must be assessed by a physician

⚕ Clinical note: This card is educational and is not medical advice, a protocol or a promise of results. Ipamorelin is investigational; any use must be individualised and supervised by a qualified physician.

Evidence: Investigational (Grade C) — limited human data, not an approved therapy · References: peer-reviewed growth-hormone secretagogue and endocrinology literature; preclinical and early-phase GHSR-1a studies; EMA/MHRA product and safety information